SCO-120 is under clinical development by Sun Pharma Advanced Research and currently in Phase I for Metastatic Breast Cancer. According to GlobalData, Phase I drugs for Metastatic Breast Cancer have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SCO-120’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SCO-120 is under development for the treatment of breast cancer and HER2 negative metastatic Breast Cancer. It is administered by oral route. The drug candidate is a selective estrogen receptor degrader which targets both wild type and mutant forms of estrogen receptor.
Sun Pharma Advanced Research overview
Sun Pharma Advanced Research (SPARC), a subsidiary of Shanghvi Finance Pvt Ltd, is a biopharmaceutical clinical research and development service provider. The company develops active pharmaceutical ingredients, formulations and drug delivery technologies for the treatment of cancer and inflammatory diseases. Its research category consists of therapeutic focus, delivery technologies, research programs and research and development pipeline. SPARC’s therapeutic focus comprises oncology, neurodegeneration, ophthalmology, dermatology and abuse-deterrent formulations. The company’s research and development pipeline includes levetiracetam ER, latanoprost BAK Free, salmeterol-fluticasone DPI, baclofen GRS, PICN, brimonidine OD, SDN – 021, SUN – K0706, SUN – 597 Topical, SUN – K0706, minocycline topical, SUN – K0954 and SDP – 037. SPARC is headquartered in Mumbai, Maharashtra, India.
For a complete picture of SCO-120’s drug-specific PTSR and LoA scores, buy the report here.